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THE UTILITY of the measurement of
oestrogen receptor (RE) content of a
breast tumour in the management of
breast cancer was first proposed by
Jensen et al. (1967). This proposal has
since been evaluated by many groups and
the measurement of the RE content of
human breast carcinomas has been shown
to be an important prognostic indicator
in early disease (Cooke et al., 1979;
Samaan et al., 1981). Its value in
therapeutic policy and predicting re-
sponse in advanced breast cancer is also
well documented (McGuire, 1980; Jensen,
1981). Various methods have been used
to measure the cytoplasmic oestrogen
receptor RE, in breast tumours (reviewed
by Leake, 1981). The most commonly
used assay is the dextran-coated char-
coal (DCC) method, and it has been
recommended that any other method be
standardized against this procedure
(EORTC Breast Co-operative Group,
1980; De Sombre et al., 1979). However,
the DCC assay has certain limitations
(Poulsen, 1981) in that it is sensitive to
low protein concentrations, high salt
concentrations (Peck & Clark, 1977), and
at the elevated temperatures required
for "exchange assays" proteolytic
degradation becomes significant. The use
of hydroxylapatite (HAP) in the assay
of RE was first used by Erdos et al.
(1970). The "batch" HAP assay has
since been developed and has been repor-
ted to overcome all of the drawbacks of
the DCC assay (Pavlick & Coulsen, 1976;
Garola & McGuire, 1977; Rosner et al.,
1980). We wished to use the HAP assay to
measure RE, and nuclear oestrogen re-
ceptors (REn) in breast tumours and
MCF-7 cells (a human breast cancer
cell line). Earlier studies on the endocrine
responsiveness of breast tumour contain-
ing RE, have shown that only 60o% of
these tumours respond (Hawkins et al.,
1980). Measurement of the RE,, content
of tumours has been reported to improve
prediction of response (Laing et al., 1977).
One of the possible reasons for the
failure of 400% RE,-positive tumours to
respond to endocrine therapy is that there
is a defect in the receptor mechanism,
distal to the hormone binding to receptor.
Such defects have been seen in animal
tumour models (Shyamala, 1972), and
failure to translocate hormone-receptor
complexes into the nucleus has been
observed in human breast tissue (Fazekas
& McFarlane, 1980; Thorsen & Stoa,
1979). It has been proposed that measure-
ment of substantial occupied amounts of
RE, by exchange assays would indicate
tumours whose translocation mechanism
is defective (Thorsen, 1980). We report
here 2 modifications to the HAP assay,
1 to the basic assay, improving the correla-
tion with the standard DCC assay. The
other modification counteracts the insta-
bility of the unoccupied RE to elevated
temperatures, even when bound to HAP.
Both modifications serve to increase the
accuracy and reproducibility of the assay
without increasing the complexity of theG. J. PRITCHARD ET AL.
procedures used, properties which are of
vital importance in the clinical situation.
We have routinely used the single
saturating dose DCC assay for the
measurement of RE,, and had previously
observed a good correlation between this
and the number of binding sites deter-
mined by Scatchard analysis (e.g. single
dose 238-8 fmol receptor/mg protein,
Scatchard analysis 245-2 fmol receptor/
mg protein). Tumours were pulverized in
liquid N2 and then homogenized in
buffer (10 mm Tris/HCl pH 7.4, 1b5 mM
EDTA, 0 5 mm monothioglycerol). The
homogenate was centrifuged (800 g, 5
min) and the supernatant used as the
crude cytosol. The 800 g pellet was washed
and then extracted with 0-6M KCI in
homogenization buffer for 1 h at 4°C.
The crude cytosol and salt extracted
pellet were spun at 105,000 g for 30 min
at 4°C. The supernatants were used as
cytosol and nuclear extract respectively.
The DCC assay was performed on cytosol
as described by Maynard & Griffiths
(1979) except that a single saturating
dose was used with or without a 100-fold
excess of unlabelled competitor (17,B-
oestradiol) to measure nonspecific binding.
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The HAP single-point assay was per-
formed by a modification of the method
of Thorsen (1979), such that the HAP-
receptor precipitate was collected on GFC
filters, on a suction manifold, for radio-
active counting, described by Rosner
et al. (1980) as a rapid method of collec-
tion and washing.
When we compared the RE, content of
20 solid tumours, measured by both DCC
and HAP single-point assays, we found a
poor correlation between the 2 results
(Fig. 1). The linear correlation coefficient
was 0 54. Scatchard analysis of binding
data from a multiple-point HAP assay
for RE, indicated interference from high-
capacity, low-affinity binding sites, such
that a non-linear plot resulted (data not
shown). This was causing our HAP
assay to overestimate the RE, content of
tumours, which is an obvious disadvant-
age when the absolute receptor content
could be used topredict the likely hormone
responsiveness of the tumours. The one
method we found to overcome this inter-
ference was to wash the HAP-labelled
receptor precipitate with 1O-6M unlabelled
oestradiol at 4°C for 15 min. When we
compared the HAP and DCC results for
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FIG. 1.-Comparison of REc values from
human tumours as determined by single-
point DCC and HAP assays (before oestra-
diol wash introduced). Linear correlation
coefficient 0-54.
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FIG. 2.-Comparison of RE, values in
human tumours as determined by single-
point DCC and modified single-point HAP
assay. Linear correlation coefficient is 0-98.
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TABLE.-A8say of cytoplasmic receptor from MCF-7 cells by the HAP method using a
single saturating dose of (3H) oestradiol (10-8M)
Receptor
Experiment fmol/mg protein % degradation
Receptor labelled 40C 300C 43 -25
(A) after HAP precipitation 303 6 172*3
Receptor labelled
(B) before HAP precipitation 218 * 7 221*2
(A) Bound to HAP and then labelled at temperatures shown.
(B) Labelled at 4°C with 10-7_N (3H) oestradiol + 10-61\ oestradilol for 2 h before binding to HAP and
incubating at the temperatures shown.
the REe content of the next 20 tumours,
we achieved a much improved linear
correlation coefficient of 0-98 (Fig. 2).
The removal of the interference from
nonspecific binding could not be achieved
using a buffer wash alone. Under the
conditions of the oestradiol wash pro-
cedure the labelled oestradiol did not
dissociate from the receptor (data not
presented).
Similar interference was seen when a
Scatchard analysis of the binding data
for the assay of total nuclear receptor
(REn) measured by HAP exchange assay
(21 h at 30°C) was performed. The use of
the oestradiol wash procedure with oestra-
diol (E2) as competitor gave similar
results to the measurement of RE,,
using diethylstilboestreol (DES) as com-
petitor (DES, Kd=501 x 1010M, nM=
107-2 fmol/mg DNA; E2+wash, Kd=
5 07 x 10-10M, nM= 123-4 fmol/mg DNA).
This modification allows the use of the
same molecular species as both ligand and
competitor. Results using this modification
are comparable with those achieved with
DES as competitor, the usual competitor
used to eliminate nonspecific and lower-
affinity binding (Leake, 1981).
When we attempted to use the HAP
exchange assay to measure occupied
cytoplasmic receptor in MCF-7 cells,
the results in the Table were obtained,
(similar results were seen in human
breast tumours). The unoccupied cyto-
plasmic receptor is unstable at the
elevated temperatures necessary for the
exchange assay, even when bound to
HAP, a procedure which is reported to
prevent such degradation (Thorsen, 1980).
This degradation, not previously noticed,
meant we could not accurately measure
the amount of total cytoplasmic binding
(occupied +unoccupied), so the number of
occupied sites could not be determined
(total-unoccupied). As occupied nuclear
receptors are stable to degradation under
these conditions (Thorsen, 1979), we
applied this principle to our problem.
The cytosol was precharged with radio-
active oestradiol, with or without the
100-fold excess of unlabelled competitor,
for 3 h at 4°C before binding to HAP,
taking care not to dilute the cytosol.
The HAP exchange assay was then
performed at 30°C for 21 h. As can be
seen (Table) the exchange assays can
now be performed without degradation
occurring. It would appear that, for
reasons not yet fully understood, occupa-
tion of the hormone binding site on the
receptor before HAP precipitation stabil-
izes the receptor in a way that is not
possible after HAP precipitation.
We believe these 2 relatively simple
modifications to the HAP receptor assay
extend its applicability and increase the
accuracy of the measurement of oestrogen
receptors in breast tumours.
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